Biodelivery Sci Intl (BDSI) 2.43 $BDSI Biotech
Post# of 273258
Posted On: 09/02/2016 5:22:00 PM
Biodelivery Sci Intl (BDSI) 2.43 $BDSI
Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.43 (-0.02), SYN: 1.58 (-0.01), RPTP: 7.28 (+0.04), INCY: 82.02 (+1.21)
BioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 7:52AM CDT
BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), GERN: 2.75 (+0.02), COLL: 8.98 (+0.15)
BioDelivery (BDSI) Posts In-Line Loss in Q2, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:22AM CDT
BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.
BDSI: 2.43 (-0.02)
BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 5:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent business highlights and upcoming milestones.
BDSI: 2.43 (-0.02)
BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:58AM CDT
Last quarter, BioDelivery's loss was in-line with expectations. Let's see how things are shaping up for the second quarter of 2016.
IPXL: 24.03 (+0.09), BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), INCY: 82.02 (+1.21)
BioDelivery Sciences Announces Randomization Target Reached in Clinical Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
PR Newswire - Thu Aug 04, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has reached its target number of subjects to be randomized in its multi-center, double-blind, placebo-controlled Phase 2b study assessing the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with painful diabetic neuropathy. Based on the timing of randomization of the last patient, BDSI now expects topline results of the study will be available by the end of this year, which puts it six to eight weeks ahead of schedule.
BDSI: 2.43 (-0.02)
BioDelivery Sciences to Host Conference Call and Webcast of Second Quarter 2016 Results on Tuesday, August 9
PR Newswire - Mon Aug 01, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host a conference call and webcast on Tuesday, August 9, at 8:00 A.M. Eastern time. During the call, management will review BDSI's second quarter 2016 financial results and provide a business update.
BDSI: 2.43 (-0.02)
Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:47AM CDT
Endo International's (ENDP) pain drug is expected to come before the FDA's Advisory Committee this fall and hence the FDA will not render its decision by Jul 29.
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), ANIP: 59.86 (-1.56), BMY: 56.35 (-0.41)
BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
PR Newswire - Wed Jun 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
BDSI: 2.43 (-0.02)
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
PR Newswire - Mon Jun 06, 10:48AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts. The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
BDSI: 2.43 (-0.02)
New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain
PR Newswire Europe - Fri Jun 03, 7:00AM CDT
Findings also show sustained pain relief with BELBUCA(TM) treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), ENL.TO: 26.37 (-0.08)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.43 (-0.02), INSY: 14.63 (+0.27), AGIO: 36.35 (-0.39), GNCA: 5.37 (+0.09)
BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
BDSI: 2.43 (-0.02)
BioDelivery-Collegium Collaborate for Onsolis in U.S.
Zacks Equity Research - Zacks Investment Research - Thu May 12, 4:34PM CDT
BioDelivery Sciences (BDSI) and Collegium Pharmaceutical, have entered into a licensing deal for Onsolis in the U.S.
BDSI: 2.43 (-0.02), HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), COLL: 8.98 (+0.15)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Thu May 12, 3:09AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $2.18 on volume of 1.6 million shares, above average daily volume of 1.2 million. In the past 52 weeks, shares of BioDelivery Sciences have traded between a low of $1.91 and a high of $9.91 and closed yesterday at $2.18, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 2.5%.
BDSI: 2.43 (-0.02)
Collegium Licenses the U.S. rights to ONSOLIS(R) from BioDelivery Sciences
GlobeNewswire - Wed May 11, 3:05PM CDT
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017.
BDSI: 2.43 (-0.02), COLL: 8.98 (+0.15)
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
PR Newswire - Wed May 11, 3:05PM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
BDSI: 2.43 (-0.02), COLL: 8.98 (+0.15)
Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.43 (-0.02), SYN: 1.58 (-0.01), RPTP: 7.28 (+0.04), INCY: 82.02 (+1.21)
BioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 7:52AM CDT
BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), GERN: 2.75 (+0.02), COLL: 8.98 (+0.15)
BioDelivery (BDSI) Posts In-Line Loss in Q2, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:22AM CDT
BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.
BDSI: 2.43 (-0.02)
BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 5:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent business highlights and upcoming milestones.
BDSI: 2.43 (-0.02)
BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:58AM CDT
Last quarter, BioDelivery's loss was in-line with expectations. Let's see how things are shaping up for the second quarter of 2016.
IPXL: 24.03 (+0.09), BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), INCY: 82.02 (+1.21)
BioDelivery Sciences Announces Randomization Target Reached in Clinical Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
PR Newswire - Thu Aug 04, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has reached its target number of subjects to be randomized in its multi-center, double-blind, placebo-controlled Phase 2b study assessing the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with painful diabetic neuropathy. Based on the timing of randomization of the last patient, BDSI now expects topline results of the study will be available by the end of this year, which puts it six to eight weeks ahead of schedule.
BDSI: 2.43 (-0.02)
BioDelivery Sciences to Host Conference Call and Webcast of Second Quarter 2016 Results on Tuesday, August 9
PR Newswire - Mon Aug 01, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host a conference call and webcast on Tuesday, August 9, at 8:00 A.M. Eastern time. During the call, management will review BDSI's second quarter 2016 financial results and provide a business update.
BDSI: 2.43 (-0.02)
Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:47AM CDT
Endo International's (ENDP) pain drug is expected to come before the FDA's Advisory Committee this fall and hence the FDA will not render its decision by Jul 29.
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), ANIP: 59.86 (-1.56), BMY: 56.35 (-0.41)
BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
PR Newswire - Wed Jun 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
BDSI: 2.43 (-0.02)
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
PR Newswire - Mon Jun 06, 10:48AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts. The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
BDSI: 2.43 (-0.02)
New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain
PR Newswire Europe - Fri Jun 03, 7:00AM CDT
Findings also show sustained pain relief with BELBUCA(TM) treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), ENL.TO: 26.37 (-0.08)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.43 (-0.02), INSY: 14.63 (+0.27), AGIO: 36.35 (-0.39), GNCA: 5.37 (+0.09)
BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
BDSI: 2.43 (-0.02)
BioDelivery-Collegium Collaborate for Onsolis in U.S.
Zacks Equity Research - Zacks Investment Research - Thu May 12, 4:34PM CDT
BioDelivery Sciences (BDSI) and Collegium Pharmaceutical, have entered into a licensing deal for Onsolis in the U.S.
BDSI: 2.43 (-0.02), HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), COLL: 8.98 (+0.15)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Thu May 12, 3:09AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $2.18 on volume of 1.6 million shares, above average daily volume of 1.2 million. In the past 52 weeks, shares of BioDelivery Sciences have traded between a low of $1.91 and a high of $9.91 and closed yesterday at $2.18, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 2.5%.
BDSI: 2.43 (-0.02)
Collegium Licenses the U.S. rights to ONSOLIS(R) from BioDelivery Sciences
GlobeNewswire - Wed May 11, 3:05PM CDT
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017.
BDSI: 2.43 (-0.02), COLL: 8.98 (+0.15)
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
PR Newswire - Wed May 11, 3:05PM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
BDSI: 2.43 (-0.02), COLL: 8.98 (+0.15)
(0)
(0)Scroll down for more posts ▼